|
Sanofi to provide support to BioNTech in manufacturing their COVID-19 vaccine to help address public health needs
|
27 January 2021 |
|
Sanofi offers to acquire Kiadis for €308 million
|
05 November 2020 |
|
Sanofi and GSK to support COVAX with 200 million doses of adjuvanted, recombinant protein-based COVID-19 vaccine
|
28 October 2020 |
|
Sanofi and Translate Bio mRNA COVID-19 vaccine candidate induced high antibody levels in preclinical studies
|
15 October 2020 |
|
Sanofi and GSK will provide up to 300 million doses of COVID-19 vaccine to the European Union
|
18 September 2020 |
|
Sanofi and GSK initiate Phase 1/2 clinical trial of COVID-19 adjuvanted recombinant protein-based vaccine candidate
|
03 September 2020 |
|
Sanofi provides update on Kevzara® (sarilumab) Phase 3 trial in severe and critically ill COVID-19 patients outside the U.S.
|
01 September 2020 |
|
Sanofi to acquire Principia Biopharma
|
18 August 2020 |
|
Sanofi and GSK selected for Operation Warp Speed to supply United States government with 100 million doses of COVID-19 vaccine
|
07 August 2020 |
|
Sanofi and Regeneron provide update on Kevzara® (sarilumab) Phase 3 U.S. trial in COVID-19 patients
|
10 July 2020 |